Improved efficacy for ezetimibe and rosuvastatin by attenuating the induction of PCSK9

Reducing circulating LDL-cholesterol (LDL-c) reduces the risk of cardiovascular disease in people with hypercholesterolemia. Current approaches to reduce circulating LDL-c include statins, which inhibit cholesterol synthesis, and ezetimibe, which blocks cholesterol absorption. Both elevate serum PCS...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Ason, Brandon, Tep, Samnang, Davis, Harry R., Xu, Yiming, Tetzloff, Glen, Galinski, Beverly, Soriano, Ferdie, Dubinina, Natalya, Zhu, Lei, Stefanni, Alice, Wong, Kenny K., Tadin-Strapps, Marija, Bartz, Steven R., Hubbard, Brian, Ranalletta, Mollie, Sachs, Alan B., Flanagan, W. Michael, Strack, Alison, Kuklin, Nelly A.
Формат: Artigo
Язык:Inglês
Опубликовано: The American Society for Biochemistry and Molecular Biology 2011
Предметы:
Research Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC3284161/
https://ncbi.nlm.nih.gov/pubmed/21262787
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1194/jlr.M013664
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы